| A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab N Hayashi, Y Tsukamoto, WM Sallas, PJ Lowe British journal of clinical pharmacology 63 (5), 548-561, 2007 | 196 | 2007 |
| Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension JL Vachiery, S Huez, H Gillies, G Layton, N Hayashi, X Gao, R Naeije British journal of clinical pharmacology 71 (2), 289-292, 2011 | 82 | 2011 |
| Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production N Hayashi, H Kinoshita, E Yukawa, S Higuchi British journal of clinical pharmacology 46 (1), 11-19, 1998 | 36 | 1998 |
| Pharmacokinetic and pharmacodynamic analysis of subcutaneous recombinant human granulocyte colony stimulating factor (lenograstim) administration N Hayashi, H Kinoshita, E Yukawa, S Higuchi The Journal of Clinical Pharmacology 39 (6), 583-592, 1999 | 33 | 1999 |
| NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis T Doi, T Hamaguchi, K Shitara, S Iwasa, Y Shimada, M Harada, K Naito, ... Cancer Chemotherapy and Pharmacology 79, 569-578, 2017 | 30 | 2017 |
| Estimation of rhG-CSF absorption kinetics after subcutaneous administration using a modified Wagner–Nelson method with a nonlinear elimination model N Hayashi, H Aso, M Higashida, H Kinoshita, S Ohdo, E Yukawa, ... European journal of pharmaceutical sciences 13 (2), 151-158, 2001 | 23 | 2001 |
| Population pharmacokinetics (PK) of sildenafil in paediatric and adult patients with pulmonary arterial hypertension (PAH) S Watt, N Hayashi, L Harnish, X Gao European Society of Cardiology Annual Meeting, 2010 | 6 | 2010 |
| Population pharmacokinetics of sildenafil in paediatric and adult patients with pulmonary arterial hypertension S Watt, N Hayashi, L Harnisch, X Gao EUROPEAN HEART JOURNAL 31, 762-763, 2010 | 5 | 2010 |
| Population PK of Sildenafil and PK/PD assessment of Exercise tolerability in children with Pulmonary Arterial Hypertension (PAH) N Hayashi, L Harnisch PAGE2009 Program and poster abstract titles, 66, 2009 | 4 | 2009 |
| Exploring oral and intravenous ibandronate dosing regimens by clinical trial simulation R Gieschke, N Hayashi OSTEOPOROSIS INTERNATIONAL 13, S23-S23, 2002 | 4 | 2002 |
| A mechanism-based PK/PD model predicts the time course of hematological responses for epoetin beta N Hayashi, KP Zuideveld, P Jordan, R Gieschke, FHLR AG PAGE Meeting, 2003 | 3 | 2003 |
| Pharmacokinetics And Pharmacodynamics Of The Dpp-4 Inhibitor, Vildagliptin, In Japanese Patients With Type 2 Diabetes.: pii-60 N Hayashi, M Karube, Y Kumagai, Y Fujita, S Irie, Y Ikeda, YL He Clinical Pharmacology & Therapeutics 81, S68, 2007 | 1 | 2007 |
| The prospect of atacicept treatment in SLE patients - based on the results of Study APRIL and other information - Yoshiya Tanaka, Naoto Hayashi, Christian Tehlirian Jpn Rheumatology 53, 522-530, 2015 | | 2015 |
| Examples of Clinical PK / PD studies and Searching Biomarkers - From the aspect of dissemination of pharmacometrics in oversea countries N Hayashi Dose Setting in Clinical Studies and Managing Risk in Clinical Development …, 2013 | | 2013 |
| The Background and progress of pharmacometrics N Hayashi Clinical Evaluation 40, 296-301, 2013 | | 2013 |
| Safety And Tolerability Of A 10-mg Intravenous Bolus Sildenafil Dose In Patients With Pulmonary Arterial Hypertension And Comparison Of Its Pharmacokinetics With A 20-mg Oral … JL Vachiery, S Huez, H Gillies, G Layton, N Hayashi, X Gao, R Naeije B58. TREATMENT OF PULMONARY ARTERIAL HYPERTENSION, A3358-A3358, 2010 | | 2010 |
| 1. 医薬品開発に利用する M&S の有用性と海外における現状 林直人 臨床薬理 41 (5), 191-198, 2010 | | 2010 |
| PK/PD モデリングを用いた用量設定のポイントと信頼性確保 林直人 Pharm stage/技術情報協会 編 7 (3), 26-30, 2007 | | 2007 |
| 臨床開発過程における PK/PD 解析 林直人 Drug metabolism and pharmacokinetics 20 (6), 8-12, 2005 | | 2005 |
Philip LoweIt's all in the dose LtdVerified email at itsallinthedose.com
